 |
 |
Clinical Trial Name - Celecoxib Treatment for Lung Cancer
| Original Study ID : ONCA-043-04S |
| NCT ID : NCT00108186 |
| Brief Title : Celecoxib Treatment for Lung Cancer |
| Official Title : Celecoxib-Mediated Inhibition of T Regulatory Cells in Human Lung Cancer |
| Brief Summary : This proposal evaluates cyclooxygenase 2 (COX-2) inhibition as a means to decrease T regulatory cell activities and thus augment immune responses against lung cancer. The broad goal focuses on understanding how COX-2 expression regulates the malignant phenotype in non small cell lung cancer in an effort to foster an informed approach for the use of COX-2 inhibitors in prevention and therapy for lung cancer. |
| Source : Department of Veterans Affairs |
| Overall Status : Recruiting |
| Start Date : October 2004 |
| End Date : June 2011 |
| Completion Date : June 2011 |
| Official Title : Phase 1 |
| Phase : Interventional |
| Study Design : Basic Science, Non-Randomized, Open Label, Placebo Control, Single Group Assignment, Bio-availability Study |
| Enrollment : 24 |
| Verification Date : May 2009 |
| First Received Date : April 14, 2005 |
| Trial Eligibility |
| Criteria : Inclusion Criteria: - Pathologically confirmed and surgically resectable non small cell lung cancer and subjects must be ineligible for or refuse, neoadjuvant therapy Exclusion Criteria: |
| Gender : Both |
| Minimum Age : 18 Years |
| Maximum Age : N/A |
| Healthy Volunteers : No |
| Facilities |
| Facility Name : VA Greater Los Angeles Healthcare System, West LA |
| Status : Recruiting |
| City : West Los Angeles |
| State : California |
| Zip Code : 90073 |
| Country : United States |
| OutComes |
| Primary OutComes |
| Measure : Measure bio-markers; safety measures |
| Time Frame : 2 years |
| Safety issue : No |
| Interventions |
| Type : Drug |
| Name : Celecoxib |
Search For Specialist
Types of Treatments
| Search Trials By |
| Research |
| Most Popular Trials |
| Library |
| Discuss |